Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pionyr was founded in 2015 by a UCSF professor and a Genentech alum. Source: BioSpace You Might Also Like Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers March 29, 2017 6 Blood Testing Startups Hoping to be The Next Theranos – The Good Version January 11, 2018 Immutep Strikes Deal with Merck to Pair Product With Keytruda in Phase II Trial March 11, 2018
Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers March 29, 2017
